Seattle Genetics, a biotechnology firm that develops medications for treating cancer, has established itself as an authority in the healthcare industry. The company’s mission is to help cancer patients through intensive medical research, new scientific discovering, and development of new drugs. Under Dr. Siegall’s management, the biotechnology heavyweight has pocketed over $300 million by collaborating and accepting license deals from major pharmaceutical companies, including GlaxoSmithKline, AbbVie, Pfizer, and Roche.
ADCETRIS is an antibody-based medication owned and marketed by Seattle Genetics. The drug earned approval from FDA back in 2011. To date, healthcare facilities have used ADCETRIS to treat over 15,000 patients with lymphoma across the globe. Dr. Siegall believes that this medication has the capability of becoming the key treatment for a variety of CD30-expressing malignancies. Currently, the firm is seeking a license from the FDA for the use of ADCETRIS in treating Hodgkin Lymphoma (HL).
According to Dr. Siegall, Seattle Genetics is currently developing seven clinical stage programs, excluding ADCETRIS. The leading ADC programs comprise of SGN-CD33A in the treatment of acute myeloid leukemia and SGN-SD1in treating non-Hodgkin lymphoma. The two programs have produced positive data that have resulted in the expansion of the clinical programs. Dr. Siegall hinted that his firm has collaborations with top pharmaceutical and biotechnology companies. Additionally, its cutting-edge technology empowers over 20 ADCs in the stage of clinical development via the company’s collaborator or proprietary programs.
About Dr. Clay Siegall
Dr. Siegall is one of the world’s top scientists and biotechnology experts. He manages Seattle Genetics, a creative biotech firm he created on a solid foundation of medical inventiveness, research, and development of cancer treatment medications. The success that Seattle Genetics enjoys today in the biotechnology world is an expression of Dr. Siegall’s creativity, personal drive, and unique research strategies. He oversaw the initial public offering of 2011 and capital raising activities that resulted in over $675 million. He has established strong alliances in the biotechnology arena. Therefore, Dr. Siegall easily identifies both private and public financiers who support his company. He sits on the boards of leading companies such as Mirna Therapeutics, Ultragenyx Pharmaceutical, as well as Alder Biopharceuticals Inc.